MBHB Attorney Taylor Weilnau on the Implications of the Supreme Court’s Skinny Label Decision in Bloomberg Law

In Bloomberg Law, MBHB attorney Taylor Weilnau discusses the Supreme Court’s unanimous decision in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. Weilnau notes that “the FDA and regulatory context was a significant component of the Court’s analysis,” and that it remains to be seen how the ruling may apply to inducement disputes outside of life sciences. Read the article.